Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J
- DOI
- 10.1038/s41591-024-03235-9
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/db08a7c9-3aab-4dc3-855e-6c6976ba67f2 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- CitationsUnresolved reference−0.25★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on overall survival (OS) from the BEACON CRC trial, which is a hard clinical outcome. However, the biomarker analyses presented in this manuscript focus on surrogate endpoints such as immune gene signatures, cytolytic score, and molecular subtypes as predictors of OS benefit. These surrogates are not validated as substitutes for clinical outcomes, and the manuscript does not provide evidence linking these biomarkers to clinical benefit beyond exploratory associations. The claim that 'higher immune signatures showed a trend towards increased OS benefit' is based on a surrogate (immune signature) without established validation for predicting clinical outcomes in this context.
“Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.”
- 02Treatment effect not shown to be clinically meaningful
The manuscript reports hazard ratios for OS benefit in subgroups, but the primary effect size for the efficacy claim is not explicitly anchored to a minimal clinically important difference or a meaningful magnitude. For example, the HR for OS with Enco+Cetux versus control in TP53 wild-type is 0.37, but the manuscript does not discuss whether this is clinically meaningful. Additionally, the biomarker associations are exploratory and not presented with effect sizes that are clearly clinically significant. The manuscript states 'trend towards increased OS benefit' without providing a clear magnitude of benefit that is clinically meaningful.
“Patients with wild-type TP53 showed greater OS benefit with Enco+Cetux (hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627) for wild type and 0.76 (95% CI, 0.547–1.060) for mutant; P interaction = 0.0276)”
- 03Other integrity concern
Trial NCT04017650 was first submitted to ClinicalTrials.gov on 2019-07-10, after the registered study start date of 2019-06-14. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04017650
reviewer’s wording
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted, prespecified retrospective biomarker analysis of a phase 3 randomized trial, with strong reporting of ethics, resources, and data availability. Minor gaps include lack of randomization method detail, no power analysis for biomarker endpoints, and no explicit reporting guideline, but these do not undermine the overall rigor.
Both reviewers classified the study as interventional, which is adopted. The analysis is a retrospective biomarker sub-study of an interventional trial; the primary trial design is interventional. The statistics verification recomputed only 2 tests (both consistent); other statistics were not machine-verified. The citation check flagged one reference as not found in registry.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.
- CONSISTENTreported p = .001 · recomputed p = <.001Reviewer 1P-value for comparison of baseline tumor size between detectable and undetectable BRAF-V600E by ctDNA.
“Compared with patients who had detectable BRAF-V600E by ctDNA genomic profiling, those who had undetectable BRAF-V600E had smaller baseline tumor sizes (median (interquartile range; IQR) 40.00 mm (28.00–72.00) versus 66.00 mm (42.00–97.00); P = 0.001)”
Taken as given: The p-value is from a two-sided Wilcoxon rank-sum test.; The test statistic is approximately normal with z = 3.3.Method: Approximated two-sided p-value from z-score using normal distribution.How we recomputed it: pZ(3.3) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2Check p-value for correlation between BRAF V600E VAF and ctDNA maxVAF.
“maxVAF by ctDNA genomic profiling correlated with BRAF-V600E VAF ( r = 0.93; P < 0.0001; Extended Data Fig. ).”
Taken as given: The correlation coefficient is 0.93.; The sample size is 404 (from the text: '368 of 404 (91.1%) had BRAF-V600E detected in both').; The p-value is two-tailed.Method: Recomputed p-value from Pearson correlation coefficient and sample size using t-distribution.How we recomputed it: pR(0.93, 404)
- lowinternal contradictionThe abstract states 'BRAF-V600E-mutant' while the main text sometimes uses 'BRAF -V600E-mutant' with a space; this is a formatting inconsistency, not a substantive contradiction.
“BRAF -V600E-mutant mCRC”
AbstractFind in source
Overstated conclusions
2 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
7 major claims checked against the paper's own evidence: all adequately supported.
- supportedReviewers 1, 2Encorafenib plus cetuximab, with or without binimetinib, improves overall survival in BRAF-V600E-mutant mCRC.The claim is supported by the primary BEACON CRC trial results, which are cited and referenced.Evidence: The primary analysis of BEACON CRC showed significant OS improvement, as stated in the introduction and discussion.
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC.
Introduction ¶1reviewer’s wording - supportedReviewers 1, 2Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.The claim is supported by the presented analyses of immune gene expression and cytolytic score.Evidence: Cox models and GSEA showed enrichment of immune genes in patients with OS benefit from Enco+Bini+Cetux; cytolytic-high tumors had longer OS in that arm.
“Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.”
AbstractFind in source - supportedReviewers 1, 2RAS, MAP2K1 and MET alterations were most commonly acquired with Enco+Cetux±Bini.The claim is supported by the ctDNA analysis of acquired alterations.Evidence: Figure 5 and text report KRAS, NRAS, MAP2K1 mutations and MET amplification as the most frequent acquired alterations.
RAS, MAP2K1 and MET alterations were most commonly acquired with Enco+Cetux±Bini.
Abstractreviewer’s wording - supportedReviewers 1, 2Baseline TP53 mutation was associated with acquired MET amplification.The claim is supported by the odds ratio analysis.Evidence: Odds ratio = 4.3; P = 0.006 for TP53 mutation and acquired MET amplification.
“baseline TP53 mutation was associated with acquired MET amplification.”
AbstractFind in source - supportedReviewer 1Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini and mutational signatures (SBS17a/b).The claim is supported by clonality analyses and mutational signature analyses.Evidence: Clonality analysis showed subclonal acquired alterations; SBS17a/b signatures were observed at EoT; mutation rate was higher in treatment arms.
“Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini and mutational signatures (SBS17a/b).”
AbstractFind in source - supportedReviewer 2Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini.The claim is supported by the clonality analysis and mutation rate comparisons.Evidence: The paper reports that acquired resistance alterations were predominantly subclonal and that the rate of acquired mutations was higher in the Enco+Cetux±Bini arms.
Acquired resistance alterations were predominately subclonal (≤ 0.3 EoT VAF/maxVAF) compared with alterations that were detected at baseline and maintained following treatment ( P < 0.0001).
Resultsreviewer’s wording - supportedReviewer 2These findings support treatment with Enco+Cetux±Bini for patients with BRAF-V600E-mutant mCRC.The claim is supported by the primary trial results and the biomarker analyses, though the biomarker analyses are exploratory.Evidence: The primary trial demonstrated OS benefit, and the biomarker analyses show consistent benefit across subgroups.
These findings support treatment with Enco+Cetux±Bini for patients with BRAF-V600E-mutant mCRC and provide insights into the biology of response and resistance to MAPK-pathway-targeted therapy.
Abstractreviewer’s wording
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on overall survival (OS) from the BEACON CRC trial, which is a hard clinical outcome. However, the biomarker analyses presented in this manuscript focus on surrogate endpoints such as immune gene signatures, cytolytic score, and molecular subtypes as predictors of OS benefit. These surrogates are not validated as substitutes for clinical outcomes, and the manuscript does not provide evidence linking these biomarkers to clinical benefit beyond exploratory associations. The claim that 'higher immune signatures showed a trend towards increased OS benefit' is based on a surrogate (immune signature) without established validation for predicting clinical outcomes in this context.
“Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.”
- INADEQUATEEffect sizeThe manuscript reports hazard ratios for OS benefit in subgroups, but the primary effect size for the efficacy claim is not explicitly anchored to a minimal clinically important difference or a meaningful magnitude. For example, the HR for OS with Enco+Cetux versus control in TP53 wild-type is 0.37, but the manuscript does not discuss whether this is clinically meaningful. Additionally, the biomarker associations are exploratory and not presented with effect sizes that are clearly clinically significant. The manuscript states 'trend towards increased OS benefit' without providing a clear magnitude of benefit that is clinically meaningful.
“Patients with wild-type TP53 showed greater OS benefit with Enco+Cetux (hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627) for wild type and 0.76 (95% CI, 0.547–1.060) for mutant; P interaction = 0.0276)”
Data authenticity concerns
1 finding · worst mediumAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
- Other integrity concernAssessed
2 integrity concerns flagged (0 high).
- mediumotherTrial NCT04017650 was first submitted to ClinicalTrials.gov on 2019-07-10, after the registered study start date of 2019-06-14. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04017650
reviewer’s wording
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites prior work on BRAF-V600E mutations, the BEACON CRC trial, and previous studies on acquired resistance alterations. It clearly states the objective to identify molecular correlates of clinical outcomes and define resistance mechanisms. The paper acknowledges gaps in prior research, such as the lack of large randomized trials studying molecular subtypes and resistance mechanisms with BRAF inhibitor combinations.
“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”
“To our knowledge, clinical associations with molecular subtypes and mechanisms of acquired resistance following treatment with a BRAF inhibitor plus an anti-EGFR antibody, with or without a MEK inhibitor, versus conventional cytotoxic chemotherapy plus an anti-EGFR antibody, have not been studied in large, randomized trials.”
“To our knowledge, clinical associations with molecular subtypes and mechanisms of acquired resistance following treatment with a BRAF inhibitor plus an anti-EGFR antibody, with or without a MEK inhibitor, versus conventional cytotoxic chemotherapy plus an anti-EGFR antibody, have not been studied in large, randomized trials.”
“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”
The BEACON CRC trial is a randomized, open-label phase 3 trial with 1:1:1 randomization. Randomization method is not explicitly described but is standard for a phase 3 trial. Blinding is described for PFS assessment (blinded independent central review). Power analysis for the primary endpoints is referenced to previous publications, but not for the biomarker analyses. Inclusion/exclusion criteria are described. Outlier handling is addressed through exclusion criteria for ctDNA analyses. Controls are the comparator arm (Cetux+chemotherapy). Independent replication is not applicable as this is a single pivotal trial.
“patients were assigned randomly 1:1:1 to receive encorafenib, binimetinib and cetuximab (Enco+Bini+Cetux); encorafenib and cetuximab (Enco+Cetux); or investigators’ choice of either cetuximab with irinotecan or FOLFIRI (control).”
“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”
“The BEACON CRC trial was a global, multicenter, randomized, open-label phase 3 trial.”
“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”
The paper reports sex and age in the patient characteristics (Supplementary Table). Demographics are described in the context of the trial population. Species/strain and housing conditions are not applicable as this is a human study. Health status is implied by inclusion criteria (mCRC with BRAF-V600E mutation).
“Heatmap of patient characteristics and molecular profiling coverage in the biomarker analysis set, across treatment arms.”
“To assess the effect of potential confounders, results based on models with adjustment of key baseline covariates (Eastern Cooperative Oncology Group performance status, C-reactive protein, number of organs, tumor status, cetuximab source and previous use of irinotecan at randomization) are provided.”
The ethics statement explicitly states approval by institutional review boards or independent ethics committees at each center, compliance with the Declaration of Helsinki and ICH-GCP, and that all patients provided written informed consent. This meets all applicable criteria.
“All patients provided written informed consent.”
“conducted in accordance with the requirements of the regulatory authorities of each country and with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council on Harmonisation.”
“All patients provided written informed consent.”
The investigational drugs (encorafenib, binimetinib, cetuximab) are named with doses and regimens. Sequencing platforms (Personalis ACE, GuardantOMNI) are identified with versions. Software tools are named with versions (e.g., CMSclassifier v.1.0.0, fgsea v.1.28.0). Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial with no wet-lab assays.
Statistical tests are named (Cox proportional hazards, Wilcoxon rank-sum, Fisher exact, McNemar, etc.). Exact p-values are reported (e.g., P = 0.001). Effect sizes with confidence intervals are reported (e.g., HR, 0.37 (95% CI, 0.224–0.627)). Software is identified (SAS v.9.4, R v.4.0). Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not independently verified due to the complexity of the analyses.
“hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627)”
“Statistical analyses were done using SAS v.9.4 or R v.4.0 and above.”
The data availability statement provides a concrete route: data can be requested from Pfizer via a secure portal with conditions and timeframe. This meets the criteria for reported_and_adequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no custom code is mentioned.
“Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data.”
“Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data.”
“Data may be requested from Pfizer trials 24 months after study completion. The BEACON CRC study was completed in November 2022. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal.”
The trial is registered (NCT02928224). Methods are detailed enough for replication. Limitations are discussed. Conclusions are proportional. Funding and COI are provided. A reporting guideline is not explicitly mentioned, but the paper follows Nature Portfolio reporting standards.
“ClinicalTrials.gov registration: NCT02928224”
“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”
“ClinicalTrials.gov registration: NCT02928224”
“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”
Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
1 finding · worst lowReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
- References not resolvable to a published paperRecomputed
Checked 57 references by DOI: 50 verified — 1 DOI unresolved, 6 no DOI (shown, not verified).
- UNRESOLVED10.3978/j.issn.2078-6891.2015.077BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesCited DOI does not resolve to any Crossref record.
- NO DOICatalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures, v.3.3No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRandomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPhase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancerNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAnnotationDbi: manipulation of SQLite-based annotations in BioconductorNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMSigDB Gene sets for multiple organisms in a tidy data format, v.6.2.1No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGuideline on the Investigation of Subgroups in Confirmatory Clinical TrialsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
6 data/code links checked; 6 live.
- datahttps://www.pfizer.com/science/clinical-trials/trial-data-and-resultsLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/study/NCT02928224LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT02928224LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT05217446LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT04017650LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT05308446LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency.
- MINORconsistencyAbstract“BRAF -V600E-mutant”→ Remove space before hyphen: BRAF-V600E-mutantInconsistent spacing in gene names.
- MINORconsistencyResults, Baseline molecular profiling“BRAF -V600E”→ Remove space before hyphen: BRAF-V600EInconsistent spacing in gene names.
- MINORconsistencyMethods, WES and analysis“TET2”→ Ensure italics for gene namesGene names should be italicized.
- MINORconsistencyAbstract“BRAF -V600E-mutant”→ BRAF-V600E-mutantInconsistent spacing around hyphen.
- MINORconsistencyResults, Fig. 2 legend“BRAF -V600E”→ BRAF-V600EInconsistent spacing around hyphen.
- MINORconsistencyMethods, WES and analysis“TET2 was excluded from further WES analyses.”→ TET2 was excluded from further WES analyses.No issue; example only.
The published work is robust and well-reported. An informed reader should weigh the retrospective nature of the biomarker analysis, the lack of power analysis for exploratory endpoints, and the minor reporting gaps. No erratum is warranted based on the identified issues, but the flagged reference should be verified.
- 1.HIGHreportingVerify the reference 'BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies' (DOI 10.3978/j.issn.2078-6891.2015.077) which was not found in Crossref/OpenAlex; correct or replace it if it is erroneous or fabricated.A reference that cannot be located in any registry is a potential fabrication signal and must be resolved before submission.
- 2.MEDIUMrigorIn the Methods, specify the randomization method (e.g., central randomization, block size) to fully address randomization_method.Both reviewers flagged the randomization method as not detailed; specifying it improves reproducibility.
- 3.MEDIUMrigorIn the Methods, provide a power analysis for the biomarker analyses, or explicitly state that the study was not powered for these exploratory endpoints.Both reviewers noted the lack of power analysis for biomarker endpoints; stating this limitation is important for interpretation.
- 4.MEDIUMstatisticsIn the Methods, explicitly state that assumptions for statistical tests (e.g., proportional hazards) were verified, or describe how violations were handled.Reviewer 1 flagged assumptions_verified as inadequate; documenting assumption checks strengthens statistical rigor.
- 5.MEDIUMstatisticsIn the Results, report exact p-values (e.g., P = 0.0276) instead of thresholds (e.g., P < 0.0001) where possible.Reviewer 2 noted that exact p-values are not always reported; exact values improve transparency.
- 6.MEDIUMreportingIn the Reporting Summary, explicitly mention adherence to a reporting guideline such as CONSORT or STROBE.Both reviewers flagged the absence of an explicit reporting guideline; referencing one improves transparency.
- 7.MEDIUMdata codeIn the Data availability, consider depositing non-identifiable aggregate data (e.g., gene expression matrices) in a public repository to enhance repository_deposit.Reviewer 2 suggested this to improve data accessibility beyond the managed-access portal.
- 8.LOWcopyeditFix inconsistent spacing in gene names: change 'BRAF -V600E-mutant' to 'BRAF-V600E-mutant' in the Abstract and Results (Fig. 2 legend).Copyedit flagged inconsistent spacing around hyphens in gene names.
- 9.LOWcopyeditEnsure gene names such as TET2 are italicized in the Methods (WES and analysis).Copyedit flagged that gene names should be italicized for consistency.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.